Orasis Pharmaceuticals raised $78 million in a Series D round led by Arboretum Ventures and Johnson & Johnson Innovation to support the commercial launch of Qlosi, a novel corrective eye drop for the treatment of presbyopia.
Orasis Pharmaceuticals raised $78 million in a Series D round led by Arboretum Ventures and Johnson & Johnson Innovation to support the commercial launch of Qlosi, a novel corrective eye drop for the treatment of presbyopia.
10/10/24, 5:45 PM
Location
ponte vedra beachMoney raised
$78 million
Industry
therapeutics
pharmaceutical
biotechnology
health care
Round Type
series d
Investors
Maverick Ventures, Sequoia Capital, Sbi (Japan) Innovation Fund, Bluestem Capital, Visionary Ventures, Freepoint Capital Group, Catalio Capital Management, Johnson & Johnson Innovation – Jjdc, Inc., Arboretum Ventures
Orasis Pharmaceuticals announced a $78 million Series D funding round to support the launch of Qlosi, an eye drop designed for presbyopia treatment. The funding included a $68 million equity component and $15 million in structured capital. The investment was backed by notable firms including Arboretum Ventures, Johnson & Johnson Innovation, and several returning investors.
Company Info
Location
ponte vedra beach, florida, united states
Additional Info
Orasis Pharmaceuticals developed Qlosi, a corrective eye drop for the treatment of presbyopia in adults. Orasis is led by a collaborative team of industry executives and eye care professionals with a broad range of experiences in research, development, and commercialization of pharmaceutical drugs, as well as finance and business development. Orasis is funded by a diverse group of sophisticated and experienced life science and healthcare investors. Orasis has offices in the United States and Israel.